高新興(300098.SZ):一季度預虧6300萬元-8900萬元
格隆匯4月14日丨高新興(300098.SZ)公佈2022年第一季度業績預吿,公司預計實現歸屬於上市公司股東的淨虧損為6300萬元-8900萬元;預計實現扣除非經常性損益後的淨虧損為6500萬元-9100萬元。
(一)報吿期內,公司第一季度收入受國內外部分地區疫情起伏的影響,供應鏈及客户交付受到一定程度的延緩,導致公司部分項目收入確認不及預期;同時,為維持公司在車聯網及智慧交通、公共安全等戰略賽道的資源聚焦、市場開拓和佈局,公司2022年第一季度存在較多的固定開支和費用。因此公司預計2022年第一季度虧損。
(二)報吿期內,預計公司非經常性損益金額約為200萬元,主要為政府補貼。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.